Repeat Dose Toxicity Study of the AV7909 Anthrax Vaccine Candidate in Juvenile Rats

International Journal of Toxicology
Amy ZmarowskiVladimir Savransky

Abstract

AV7909 is a next-generation anthrax vaccine candidate indicated for post-exposure prophylaxis of exposure to Bacillus anthracis. AV7909 consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and the immunostimulatory Toll-like receptor 9 agonist oligodeoxynucleotide adjuvant, CPG 7909. Safety testing for pediatric population is warranted to support the potential emergency use of AV7909 in children. This study was conducted to investigate the local tolerance and potential systemic toxicity and their reversibility in juvenile rats by repeat intramuscular injections of the AV7909 vaccine candidate. Animals were dosed on postnatal day (PND) 21 (at weaning), PND 28, and PND 35, with the test article (AV7909), the adjuvant alone (Alhydrogel + CPG 7909), or sterile water for injection. Core group animals were necropsied on PND 37 and recovery group on PND 49. Study end points included survival, clinical observations, injection site observations, body weights, clinical pathology (hematology, coagulation, and clinical chemistry), pro-inflammatory biomarker analysis (alpha-2 macroglobulin [A2M] and alpha-1 acid glycoprotein [AGP]), and anatomic pathology. Immune response to vaccination was measured using the high-throughput a...Continue Reading

References

May 1, 1986·Infection and Immunity·B E IvinsS H Leppla
Mar 1, 1994·Biologicals : Journal of the International Association of Biological Standardization·R K Gupta, G R Siber
Jan 1, 1993·Vaccine·R K GuptaC K Gupta
Feb 17, 2001·Journal of Applied Toxicology : JAT·K H DiehlUNKNOWN European Federation of Pharmaceutical Industries Association and European Centre for the Validation of Alternative Methods
Aug 2, 2005·Nature Reviews. Immunology·Reina E Mebius, Georg Kraal
Aug 4, 2005·Journal of Pharmaceutical and Biomedical Analysis·Sarah K Branch
Sep 1, 2009·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Cynthia FrancoA Thomas Waytes
Jul 30, 2011·Prehospital Emergency Care : Official Journal of the National Association of EMS Physicians and the National Association of State EMS Directors·UNKNOWN National Association of EMS Physicians
Aug 30, 2013·Clinical and Vaccine Immunology : CVI·Allan WatkinsonJeremy H Lakey
Feb 19, 2015·Human Vaccines & Immunotherapeutics·Peng HeZhongyu Hu
Mar 5, 2016·Expert Review of Vaccines·Jarad M SchifferConrad P Quinn
Jun 11, 2019·International Journal of Toxicology·Vladimir SavranskyJeffry Shearer

❮ Previous
Next ❯

Citations

Jul 21, 2021·International Journal of Toxicology·Veena V RaoVladimir Savransky

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.